MX337712B - Derivados de acido 3-fenilpropionico ramificados y su uso. - Google Patents

Derivados de acido 3-fenilpropionico ramificados y su uso.

Info

Publication number
MX337712B
MX337712B MX2013011774A MX2013011774A MX337712B MX 337712 B MX337712 B MX 337712B MX 2013011774 A MX2013011774 A MX 2013011774A MX 2013011774 A MX2013011774 A MX 2013011774A MX 337712 B MX337712 B MX 337712B
Authority
MX
Mexico
Prior art keywords
branched
acid derivatives
phenylpropionic acid
treating
preventing
Prior art date
Application number
MX2013011774A
Other languages
English (en)
Other versions
MX2013011774A (es
Inventor
Karl-Heinz Schlemmer
Johannes-Peter Stasch
Thomas Lampe
Andreas Knorr
Frank Wunder
Elisabeth Woltering
Volkhart Min-Jian Li
Michael Hahn
Eva-Maria Becker-Pelster
Friedericke Stoll
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of MX2013011774A publication Critical patent/MX2013011774A/es
Publication of MX337712B publication Critical patent/MX337712B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/14—Preparation of carboxylic acid amides by formation of carboxamide groups together with reactions not involving the carboxamide groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/53—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C07C233/55—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a carbon atom of an unsaturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C235/38—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente solicitud se refiere a nuevos derivados de ácido 3-fenilpropiónico que poseen en la posición 3 un sustituyente de alquilo ramificado o cíclico, a procedimientos para su preparación y a su uso para el tratamiento y/o la prevención de enfermedades, así como a su uso para la preparación de medicamentos para el tratamiento y/o la prevención de enfermedades, en particular para el tratamiento y/o la prevención de afecciones cardiovasculares.
MX2013011774A 2011-04-13 2012-03-28 Derivados de acido 3-fenilpropionico ramificados y su uso. MX337712B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102011007272A DE102011007272A1 (de) 2011-04-13 2011-04-13 Verzweigte 3-Phenylpropionsäure-Derivate und ihre Verwendung
PCT/EP2012/055474 WO2012139888A1 (de) 2011-04-13 2012-03-28 Verzweigte 3-phenylpropionsäure-derivate und ihre verwendung

Publications (2)

Publication Number Publication Date
MX2013011774A MX2013011774A (es) 2013-11-01
MX337712B true MX337712B (es) 2016-03-15

Family

ID=45928886

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013011774A MX337712B (es) 2011-04-13 2012-03-28 Derivados de acido 3-fenilpropionico ramificados y su uso.

Country Status (42)

Country Link
US (6) US8796335B2 (es)
EP (1) EP2697191B1 (es)
JP (1) JP5911950B2 (es)
KR (1) KR101944559B1 (es)
CN (1) CN103796989B (es)
AP (1) AP3482A (es)
AR (1) AR085586A1 (es)
AU (1) AU2012242122B2 (es)
BR (1) BR112013026466B1 (es)
CA (1) CA2832970C (es)
CL (1) CL2013002902A1 (es)
CO (1) CO6801742A2 (es)
CR (1) CR20130524A (es)
CU (1) CU24183B1 (es)
CY (1) CY1117183T1 (es)
DE (1) DE102011007272A1 (es)
DK (1) DK2697191T3 (es)
DO (1) DOP2013000239A (es)
EA (1) EA023990B1 (es)
EC (1) ECSP13012966A (es)
ES (1) ES2561753T3 (es)
GT (1) GT201300243A (es)
HR (1) HRP20160100T1 (es)
HU (1) HUE026859T2 (es)
IL (1) IL228677A (es)
JO (1) JO3091B1 (es)
MA (1) MA35039B1 (es)
ME (1) ME02310B (es)
MX (1) MX337712B (es)
MY (1) MY173877A (es)
PE (1) PE20140630A1 (es)
PL (1) PL2697191T3 (es)
PT (1) PT2697191E (es)
RS (1) RS54527B1 (es)
SG (2) SG193941A1 (es)
SI (1) SI2697191T1 (es)
TN (1) TN2013000411A1 (es)
TW (1) TWI549933B (es)
UA (1) UA110054C2 (es)
UY (1) UY33970A (es)
WO (1) WO2012139888A1 (es)
ZA (1) ZA201308490B (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102009012314A1 (de) * 2009-03-09 2010-09-16 Bayer Schering Pharma Aktiengesellschaft Oxo-heterocyclisch substituierte Alkylcarbonsäuren und ihre Verwendung
DE102009046115A1 (de) 2009-10-28 2011-09-08 Bayer Schering Pharma Aktiengesellschaft Substituierte 3-Phenylpropansäuren und ihre Verwendung
BR112013013663A2 (pt) 2010-12-07 2016-09-06 Bayer Ip Gmbh ácidos 1-benzilcicloalquilcarboxílicos substituídos e sua utilização
DE102011007272A1 (de) 2011-04-13 2012-10-18 Bayer Pharma Aktiengesellschaft Verzweigte 3-Phenylpropionsäure-Derivate und ihre Verwendung
BR122020001312B1 (pt) 2011-11-25 2022-02-15 Adverio Pharma Gmbh Processo para preparação de 5-flúor-1h-pirazolopiridinas substituídas, e compostos intermediários
DE102012208530A1 (de) 2012-05-22 2013-11-28 Bayer Pharma AG Substituierte Piperidinoacetamide und ihre Verwendung
PL2927231T3 (pl) * 2012-11-30 2018-01-31 Astellas Pharma Inc Związki imidazopirydyny
WO2014186704A2 (en) * 2013-05-17 2014-11-20 N30 Pharmaceuticals, Inc. Novel compounds for the treatment of cystic fibrosis
US10265314B2 (en) 2013-07-25 2019-04-23 Bayer Pharma Aktiengesellschaft SGC stimulators in combination with additional treatment for the therapy of cystic fibrosis
TW201625601A (zh) 2014-07-02 2016-07-16 諾華公司 噻吩－２－基－吡啶－２－基－１ｈ－吡唑－４－羧酸衍生物及其作為可溶性鳥苷酸環化酶活化劑之用途
TW201625584A (zh) 2014-07-02 2016-07-16 諾華公司 茚滿及吲哚啉衍生物及其作為可溶性鳥苷酸環化酶活化劑之用途
TW201625586A (zh) 2014-07-02 2016-07-16 諾華公司 環己烯－１－基－吡啶－２－基－１ｈ－吡唑－４－羧酸衍生物及其作為可溶性鳥苷酸環化酶活化劑之用途
CN107257790A (zh) 2014-12-18 2017-10-17 拜耳医药股份有限公司 取代的吡啶基‑环烷基‑羧酸、包含它们的组合物及其医学用途
TN2017000465A1 (en) 2015-05-06 2019-04-12 Bayer Pharma AG The use of sgc stimulators, sgc activators, alone and combinations with pde5 inhibitors for the treatment of digital ulcers (du) concomitant to systemic sclerosis (ssc)
HRP20201932T4 (hr) 2015-07-23 2024-02-16 Bayer Pharma Aktiengesellschaft Stimulatori / aktivatori topive gvanilat-ciklaze u kombinaciji s nep-inhibitorom i/ili angiotenzin aii-antagonistom i njihova uporaba
EP3525779B1 (de) 2016-10-11 2024-06-05 Bayer Pharma Aktiengesellschaft Kombination enthaltend den sgc stimulator vericuguat und den mineralcorticoid-rezeptor-antagonist finerenone
US11331308B2 (en) 2016-10-11 2022-05-17 Bayer Pharma Aktiengesellschaft Combination containing sGC activators and mineralocorticoid receptor antagonists
WO2018153899A1 (de) 2017-02-22 2018-08-30 Bayer Pharma Aktiengesellschaft Selektive partielle adenosin a1 rezeptor-agonisten in kombination mit stimulatoren und/oder aktivatoren der löslichen guanylatcyclase (sgc)
EA202091020A1 (ru) 2017-10-24 2020-07-24 Байер Акциенгезельшафт Замещенные имидазопиридинамиды и их применение
WO2019081456A1 (en) 2017-10-24 2019-05-02 Bayer Aktiengesellschaft USE OF SGC ACTIVATORS AND STIMULATORS COMPRISING A BETA2 SUBUNIT
RU2020121714A (ru) 2017-12-01 2022-01-04 Байер Фарма Акциенгезельшафт Способ получения (3s)-3-(4-хлор-3-{ [(2s,3r)-2-(4-хлорфенил)-4,4,4-трифтор-3-метилбутаноил]амино} фенил)-3-циклопропилпропановой кислоты и её кристаллической формы для применения в качестве фармацевтического активного вещества
EP3498298A1 (en) 2017-12-15 2019-06-19 Bayer AG The use of sgc stimulators and sgc activators alone or in combination with pde5 inhibitors for the treatment of bone disorders including osteogenesis imperfecta (oi)
WO2019211081A1 (en) 2018-04-30 2019-11-07 Bayer Aktiengesellschaft The use of sgc activators and sgc stimulators for the treatment of cognitive impairment
CA3100096A1 (en) 2018-05-15 2019-11-21 Bayer Aktiengesellschaft 1,3-thiazol-2-yl substituted benzamides for the treatment of diseases associated with nerve fiber sensitization
US11508483B2 (en) 2018-05-30 2022-11-22 Adverio Pharma Gmbh Method of identifying a subgroup of patients suffering from dcSSc which benefits from a treatment with sGC stimulators and sGC activators in a higher degree than a control group
JOP20210019A1 (ar) * 2018-07-24 2021-01-24 Bayer Ag شكل جرعة صيدلانية تعطى عن طريق الفم ذات اطلاق مُعدّل
US10905667B2 (en) * 2018-07-24 2021-02-02 Bayer Pharma Aktiengesellschaft Orally administrable modified-release pharmaceutical dosage form
JP2021531297A (ja) * 2018-07-24 2021-11-18 バイエル・アクチエンゲゼルシヤフト 経口投与可能であり、修飾された放出を有する薬学的投薬形態
CN113330030A (zh) 2019-01-17 2021-08-31 拜耳公司 确定受试者是否适于用可溶性鸟苷酸环化酶(sGC)的激动剂治疗的方法
WO2020164008A1 (en) 2019-02-13 2020-08-20 Bayer Aktiengesellschaft Process for the preparation of porous microparticles
WO2020216669A1 (de) 2019-04-23 2020-10-29 Bayer Aktiengesellschaft Phenylsubstituierte imidazopyridinamide und ihre verwendung
MX2021013616A (es) 2019-05-07 2021-12-10 Bayer Ag Compuestos inhibidores de la masp y usos de estos.
TW202112359A (zh) 2019-06-07 2021-04-01 德商拜耳廠股份有限公司 sGC活化劑於治療眼科疾病之用途
EP3822268A1 (en) 2019-11-15 2021-05-19 Bayer Aktiengesellschaft Substituted hydantoinamides as adamts7 antagonists
EP3822265A1 (en) 2019-11-15 2021-05-19 Bayer AG Substituted hydantoinamides as adamts7 antagonists
EP4011874A1 (en) 2020-12-10 2022-06-15 Bayer Aktiengesellschaft Substituted pyrazolo piperidine carboxylic acids
JP7458683B2 (ja) 2020-12-10 2024-04-01 バイエル・アクチエンゲゼルシヤフト 眼科疾患の治療のためのｓＧＣ活性化剤の使用
CA3204595A1 (en) 2020-12-10 2022-06-16 Bayer Aktiengesellschaft Substituted pyrazolyl piperidine carboxylic acids
EP4011873A1 (en) 2020-12-10 2022-06-15 Bayer Aktiengesellschaft Substituted pyrazolo piperidine carboxylic acids
WO2022122914A1 (en) 2020-12-10 2022-06-16 Bayer Aktiengesellschaft Substituted pyrazolo piperidine carboxylic acids
JP2024518991A (ja) * 2021-05-14 2024-05-08 メッドシャイン ディスカバリー インコーポレイテッド アルキルカルボン酸化合物及びその使用
WO2023275796A1 (en) * 2021-07-01 2023-01-05 Novartis Ag Heterocyclic derivatives as sphingosine-1-phosphate 3 inhibitors
TW202317510A (zh) * 2021-07-15 2023-05-01 大陸商江蘇恆瑞醫藥股份有限公司 ３－苯基丙酸類化合物、其製備方法及其在醫藥上的應用
WO2023155873A1 (zh) * 2022-02-18 2023-08-24 江苏恒瑞医药股份有限公司 羧酸类化合物、其制备方法及其在医药上的应用
WO2023237577A1 (en) 2022-06-09 2023-12-14 Bayer Aktiengesellschaft Soluble guanylate cyclase activators for use in the treatment of heart failure with preserved ejection fraction in women
WO2024099361A1 (zh) * 2022-11-08 2024-05-16 南京明德新药研发有限公司 一种烷基羧酸类化合物的晶型及其应用

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
GB1478759A (en) 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
US4063064A (en) 1976-02-23 1977-12-13 Coherent Radiation Apparatus for tracking moving workpiece by a laser beam
US4111202A (en) 1976-11-22 1978-09-05 Alza Corporation Osmotic system for the controlled and delivery of agent over time
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4765989A (en) 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
NZ206600A (en) 1983-05-11 1987-01-23 Alza Corp Osmotic drug delivery device
ATE72111T1 (de) 1987-01-14 1992-02-15 Ciba Geigy Ag Therapeutisches system fuer schwerloesliche wirkstoffe.
US5041453A (en) 1990-05-30 1991-08-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Quinolinyl-benzoheterobicyclic derivatives as antagonists of leukotriene D4
AU675689B2 (en) 1992-12-01 1997-02-13 Merck & Co., Inc. Fibrinogen receptor antagonists
DE4301900A1 (de) 1993-01-25 1994-07-28 Bayer Ag 2-Oxochinolin-1-yl-methylphenylessigsäurederivate
US5643957A (en) 1993-04-22 1997-07-01 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
DE4326344A1 (de) 1993-08-05 1995-02-09 Thomae Gmbh Dr K Carbonamide, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
FR2722145B1 (fr) 1994-07-05 1996-09-27 Michelin & Cie Bande de roulement pour pneumatique hivernaux
NL9401707A (nl) 1994-10-17 1996-06-03 Dsm Nv Werkwijze voor de bereiding van 3-fenylpropaanzuur.
DE4443892A1 (de) 1994-12-09 1996-06-13 Bayer Ag 4-(Chinolin-2-yl-methoxy)-phenyl-essigsäurederivate
US5650386A (en) 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
DE19546918A1 (de) 1995-12-15 1997-06-19 Bayer Ag Bicyclische Heterocyclen
EP0802192A1 (de) 1996-04-17 1997-10-22 Bayer Ag Heterocyclisch-substituierte Phenylglycinolamide mit antiatherosklerotischer Wirkung und Verfahren zu ihrer Herstellung
DE19747261A1 (de) 1997-10-25 1999-04-29 Bayer Ag Osmotisches Arzneimittelfreisetzungssystem
DE19821483A1 (de) 1998-05-14 1999-11-18 Hoechst Marion Roussel De Gmbh Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
AU767123B2 (en) 1999-02-24 2003-10-30 F. Hoffmann-La Roche Ag Phenyl- and pyridinyl derivatives
YU72201A (sh) 1999-04-28 2005-07-19 Aventis Pharma Deutschland Gmbh. Derivati di-aril kiseline kao ppar receptorski ligandi
ES2261202T3 (es) 1999-04-28 2006-11-16 Sanofi-Aventis Deutschland Gmbh Derivados de acido de triarilo como ligandos para el receptor ppar.
DE19929065A1 (de) 1999-06-25 2000-12-28 Bayer Ag Kombination von MTP-Inhibitoren und HMG-CoA-Reduktase-Inhibitoren und ihre Verwendung in Arzneimitteln
DE19943636A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
EP1229010A1 (en) 1999-10-01 2002-08-07 Japan Energy Corporation Novel diarylamide derivatives and use thereof as medicines
TWI262185B (en) 1999-10-01 2006-09-21 Eisai Co Ltd Carboxylic acid derivatives having anti-hyperglycemia and anti-hyperlipemia action, and pharmaceutical composition containing the derivatives
CA2410647C (en) 2000-05-29 2010-02-09 Kyorin Pharmaceutical Co., Ltd. Substituted phenylpropanoic acid derivatives
WO2002016311A1 (fr) 2000-08-22 2002-02-28 Ono Pharmaceutical Co., Ltd. Derives d'acide carboxylique, procede de production de ceux-ci et medicaments contenant ceux-ci comme principe actif
AU2001288067A1 (en) 2000-09-21 2002-04-02 Sankyo Company Limited Phenylpropionic acid derivatives
EP1330432A2 (en) 2000-11-04 2003-07-30 Aventis Pharma Limited Substituted alkanoic acids
AR031176A1 (es) 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
EP1348698A4 (en) 2000-12-05 2005-01-19 Kyorin Seiyaku Kk SUBSTITUTED CARBOXYLENE DERIVATIVES
EP1357115B1 (en) 2000-12-28 2009-06-17 Takeda Pharmaceutical Company Limited Alkanoic acid derivatives, process for their production and use thereof
US7241785B2 (en) 2001-03-23 2007-07-10 Takeda Pharmaceutical Company Limited Five-membered heterocyclic alkanoic acid derivative
JP4549021B2 (ja) 2001-03-30 2010-09-22 エーザイ・アール・アンド・ディー・マネジメント株式会社 ベンゼン化合物およびその塩
US20030105097A1 (en) 2001-05-14 2003-06-05 Pfizer Inc. Alkylamide compounds
JP4529119B2 (ja) 2001-08-09 2010-08-25 小野薬品工業株式会社 カルボン酸誘導体化合物およびその化合物を有効成分として含有する薬剤
EP1452521A4 (en) 2001-08-17 2007-03-14 Eisai R&D Man Co Ltd CYCLIC COMPOUND AND AGONIST OF PPAR RECEPTOR
US20030161882A1 (en) 2002-02-01 2003-08-28 Waterman Kenneth C. Osmotic delivery system
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
EP1541564A1 (en) 2002-09-10 2005-06-15 Takeda Pharmaceutical Company Limited Five-membered heterocyclic compounds
US20050234066A1 (en) 2004-04-15 2005-10-20 Agouron Pharmaceuticals, Inc. Alpha substituted carboxylic acids
US20050187266A1 (en) 2003-04-15 2005-08-25 Pfizer Inc Alpha substituted carboxylic acids
WO2004099170A2 (en) 2003-04-30 2004-11-18 The Institutes For Pharmaceutical Discovery, Llc Phenyl substituted carboxylic acids as inhibitors of protein tyrosine phosphatase-1b
EP1737809B1 (en) 2004-02-27 2013-09-18 Amgen, Inc Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders
EP1786821B1 (en) 2004-07-19 2009-09-16 Intercasting Corporation Dynamic knowledge-based networking system and method
WO2006030036A1 (es) 2004-08-10 2006-03-23 Microelectronica Española, S.A.U Unidad de procesado y método de gestión de memoria en sistemas de procesado con recursos limitados
MY145712A (en) 2004-09-15 2012-03-30 Janssen Pharmaceutica Nv 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
JP2008518926A (ja) 2004-10-28 2008-06-05 ジ インスティチューツ フォー ファーマシューティカル ディスカバリー、エルエルシー 置換フェニルアルカン酸
CA2587566A1 (en) * 2004-11-18 2006-05-26 The Institutes For Pharmaceutical Discovery, Llc Heterocyclylbiphenyl derivates as protein tyrosine phosphatase inhibitors
US20060167044A1 (en) 2004-12-20 2006-07-27 Arnaiz Damian O Piperidine derivatives and their use as anti-inflammatory agents
DE102004062475A1 (de) 2004-12-24 2006-07-06 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung
PL372356A1 (pl) 2005-01-20 2006-07-24 ADAMED Sp.z o.o. Nowe związki, pochodne kwasu 3-fenylopropionowego
JP4324221B2 (ja) 2005-08-26 2009-09-02 株式会社医薬分子設計研究所 Ｐｐａｒアゴニスト活性を有する誘導体
DE102005050377A1 (de) 2005-10-21 2007-04-26 Bayer Healthcare Ag Heterocyclische Verbindungen und ihre Verwendung
CN101116660A (zh) * 2006-08-04 2008-02-06 瑟维尔实验室 抗动脉粥样化血栓形成的化合物在获得用于治疗血管疾病的药物中的用途
US20110092554A1 (en) 2007-11-19 2011-04-21 Richard Chesworth 1,3,5 tri-subtituted benzenes for treatment of alzheimer's disease and other disorders
DE102008018675A1 (de) * 2008-04-14 2009-10-15 Bayer Schering Pharma Aktiengesellschaft Oxo-heterocyclisch substituierte Carbonsäure-Derivate und ihre Verwendung
KR20110022089A (ko) 2008-06-27 2011-03-04 노파르티스 아게 유기 화합물
EP2179993A1 (de) 2008-10-21 2010-04-28 Bayer Schering Pharma Aktiengesellschaft Sulfoxidsubstituierte Anilinopyrimidinderivative als CDK-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
EP2179992A1 (de) 2008-10-21 2010-04-28 Bayer Schering Pharma Aktiengesellschaft Sulfonsubstituierte Anlinopyrimidinderivative als CDK-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
DE102008059206A1 (de) 2008-11-27 2010-06-10 Bayer Schering Pharma Aktiengesellschaft Pharmazeutische Darreichungsform enthaltend Nifedipin oder Nisoldipin und einen Angiotensin-II Antagonisten und/oder ein Diuretikum
DE102009012314A1 (de) 2009-03-09 2010-09-16 Bayer Schering Pharma Aktiengesellschaft Oxo-heterocyclisch substituierte Alkylcarbonsäuren und ihre Verwendung
DE102009046115A1 (de) * 2009-10-28 2011-09-08 Bayer Schering Pharma Aktiengesellschaft Substituierte 3-Phenylpropansäuren und ihre Verwendung
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
WO2012004258A1 (de) 2010-07-09 2012-01-12 Bayer Pharma Aktiengesellschaft Annellierte pyrimidine und triazine und ihre verwendung zur behandlung bzw. prophylaxe von herz-kreislauf-erkrankungen
DE102010040233A1 (de) 2010-09-03 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Bicyclische Aza-Heterocyclen und ihre Verwendung
DE102010043379A1 (de) 2010-11-04 2012-05-10 Bayer Schering Pharma Aktiengesellschaft Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung
BR112013013663A2 (pt) 2010-12-07 2016-09-06 Bayer Ip Gmbh ácidos 1-benzilcicloalquilcarboxílicos substituídos e sua utilização
DE102011007272A1 (de) * 2011-04-13 2012-10-18 Bayer Pharma Aktiengesellschaft Verzweigte 3-Phenylpropionsäure-Derivate und ihre Verwendung
DE102012208530A1 (de) 2012-05-22 2013-11-28 Bayer Pharma AG Substituierte Piperidinoacetamide und ihre Verwendung
EP2875003B1 (de) 2012-07-20 2016-11-16 Bayer Pharma Aktiengesellschaft Neue 5-aminotetrahydrochinolin-2-carbonsäuren und ihre verwendung
US11331308B2 (en) 2016-10-11 2022-05-17 Bayer Pharma Aktiengesellschaft Combination containing sGC activators and mineralocorticoid receptor antagonists
RU2020121714A (ru) 2017-12-01 2022-01-04 Байер Фарма Акциенгезельшафт Способ получения (3s)-3-(4-хлор-3-{ [(2s,3r)-2-(4-хлорфенил)-4,4,4-трифтор-3-метилбутаноил]амино} фенил)-3-циклопропилпропановой кислоты и её кристаллической формы для применения в качестве фармацевтического активного вещества
JP2021531297A (ja) 2018-07-24 2021-11-18 バイエル・アクチエンゲゼルシヤフト 経口投与可能であり、修飾された放出を有する薬学的投薬形態
AR117614A1 (es) 2018-07-24 2021-08-18 Bayer Ag Forma de dosificación farmacéutica administrable por vía oral con liberación modificada
US10905667B2 (en) 2018-07-24 2021-02-02 Bayer Pharma Aktiengesellschaft Orally administrable modified-release pharmaceutical dosage form
TW202112359A (zh) 2019-06-07 2021-04-01 德商拜耳廠股份有限公司 sGC活化劑於治療眼科疾病之用途

Also Published As

Publication number Publication date
DOP2013000239A (es) 2014-01-15
CL2013002902A1 (es) 2014-02-14
PL2697191T3 (pl) 2016-04-29
JO3091B1 (ar) 2017-03-15
EP2697191A1 (de) 2014-02-19
CA2832970A1 (en) 2012-10-18
TN2013000411A1 (en) 2015-03-30
EA201301154A1 (ru) 2014-04-30
SG193941A1 (en) 2013-11-29
KR101944559B1 (ko) 2019-01-31
CO6801742A2 (es) 2013-11-29
US10023528B2 (en) 2018-07-17
US11377417B2 (en) 2022-07-05
AU2012242122B2 (en) 2017-06-01
SG10201602852WA (en) 2016-05-30
CN103796989B (zh) 2017-03-01
TW201302674A (zh) 2013-01-16
MA35039B1 (fr) 2014-04-03
US20140309307A1 (en) 2014-10-16
ME02310B (me) 2016-06-20
CA2832970C (en) 2019-06-04
EA023990B1 (ru) 2016-08-31
AP2013007164A0 (en) 2013-10-31
HUE026859T2 (en) 2016-07-28
DE102011007272A1 (de) 2012-10-18
KR20140021008A (ko) 2014-02-19
US8796335B2 (en) 2014-08-05
US20200385335A1 (en) 2020-12-10
SI2697191T1 (sl) 2016-03-31
PE20140630A1 (es) 2014-05-24
US10259776B2 (en) 2019-04-16
NZ616274A (en) 2016-02-26
ES2561753T3 (es) 2016-02-29
US20190185415A1 (en) 2019-06-20
RS54527B1 (en) 2016-06-30
UY33970A (es) 2012-11-30
EP2697191B1 (de) 2015-11-18
DK2697191T3 (en) 2016-02-15
BR112013026466B1 (pt) 2022-05-10
BR112013026466A2 (pt) 2020-09-01
CU24183B1 (es) 2016-07-29
CU20130137A7 (es) 2014-01-29
JP2014522383A (ja) 2014-09-04
MY173877A (en) 2020-02-26
IL228677A (en) 2017-06-29
CN103796989A (zh) 2014-05-14
WO2012139888A1 (de) 2012-10-18
HRP20160100T1 (hr) 2016-02-26
AP3482A (en) 2015-12-31
GT201300243A (es) 2015-02-23
PT2697191E (pt) 2016-03-11
US20130079412A1 (en) 2013-03-28
ECSP13012966A (es) 2013-11-29
TWI549933B (zh) 2016-09-21
MX2013011774A (es) 2013-11-01
UA110054C2 (uk) 2015-11-10
US20180282262A1 (en) 2018-10-04
AU2012242122A1 (en) 2013-10-24
IL228677A0 (en) 2013-12-31
US20160264515A1 (en) 2016-09-15
CY1117183T1 (el) 2017-04-05
AR085586A1 (es) 2013-10-09
ZA201308490B (en) 2015-08-26
JP5911950B2 (ja) 2016-04-27
CR20130524A (es) 2014-01-31

Similar Documents

Publication Publication Date Title
TN2013000411A1 (en) Branched 3-phenylpropionic acid derivatives and the use thereof
PH12015501494A1 (en) Method for producing substituted 5-fluoro-1h-pyrazolopyrimidines
PH12014502496A1 (en) Bicyclically substituted uracils and the use thereof
EP2801611A4 (en) MICRO-ORGANISM FOR THE PRODUCTION OF L-AMINO ACID AND PROCESS FOR THE PRODUCTION OF L-AMINO ACIDS THEREWITH
MX362689B (es) Procedimiento de preparacion de derivados de acido 3,5-bis(fluoroalquil)pirazol-4-carboxilico y 3,5-bis(fluoroalquil) pirazoles.
HK1199242A1 (zh) 生產 -丁二烯的方法
WO2011009532A3 (de) 17-hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-benzyliden-derivate, verfahren zu deren herstellung und deren verwendung zur behandlung von krankheiten
MX2012010317A (es) ß-HIDROXIALQUILAMIDAS, METODO PARA SU PRODUCCION Y SU USO.
GB2523674A (en) Compounds as inhibitor of DNA double-strand break repair, methods and applications thereof
MX343856B (es) Procedimiento para la preparación de derivados 1-h-pirrolidin-2,4-diona.
TN2015000095A1 (en) Macrolide derivatives, preparation thereof and therapeutic use thereof
MX361998B (es) Procedimiento de preparacion de derivados de acido 4-haloalquil-3-mercapto-2 sustituido-hidroxibenzoico.
WO2014009204A8 (de) Oxasilacyclen und verfahren zu deren herstellung
MX2011012233A (es) Soluciones de retinoide topicas.
PH12015500262A1 (en) Novel pyridine derivatives
EP2886548A4 (en) PROCESS FOR THE PREPARATION OF A BORINIC ACID DERIVATIVE AND NEW BORIC ACID DERIVATIVE
HRP20180032T8 (hr) Postupak dobivanja spoja 4,4,7-trifluor-1,2,3,4-tetrahidro-5h-1-benzazepina i međuprodukta u njegovoj sintezi
PH12014501760A1 (en) Method for stereoselective synthesis of 1,4-protected 9-hydroxy-5-oxo-1,4-diaza-spiro[5.5]undecanes
MX2013010001A (es) Derivados de androstanediol como compuestos reguladores del crecimiento de las plantas.
MX2013002990A (es) Nuevo procedimiento de sintesis de la ivabradina y de sus sales de adicion a un acido farmaceuticamente aceptable.
TN2014000227A1 (en) Method for producing substituted 5-fluoro-1h-pyrazolopyridines
TN2013000243A1 (en) Substituted 1-benzylcycloalkylcarboxlic acids and use thereof
TN2013000128A1 (en) Process for preparing pan-cdk inhibitors of the formula (1), and intermediates in the preparation
UA74450U (ru) Способ лечения врожденных пневмоний у доношенных новорожденных детей
UA69939U (ru) Способ фармакокорекции гемической гипоксии

Legal Events

Date Code Title Description
FG Grant or registration